Drug intelligence / Profile preview

AIP-202

Development stage: Preclinical
Lead developer: AIP
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

AIP-202 is a radiopharmaceutical diagnostic candidate being developed by Advanced Innovative Partners (AIP Medical) for the detection and imaging of lung cancer. Currently in the preclinical stage, this agent is designed to utilize targeted radioisotopes to provide high-sensitivity imaging, potentially aiding in the early diagnosis and characterization of pulmonary malignancies. As a diagnostic radiopharmaceutical, it likely consists of a targeting moiety conjugated to a radioisotope suitable for imaging techniques such as PET or SPECT. AIP-202 is part of a broader oncology pipeline focused on both diagnostic and therapeutic radiopharmaceutical innovations.

Beyond the preview

Go deeper on AIP-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIP-202.

Explore the full profile